Photo: AdobeStock, Evolva License
New findings from the RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study, shows that daily supplementation with the branded resveratrol, Veri-te, supports cognitive health in postmenopausal women.
9 Sep 2020 — Evolva announced the publication of Regular Supplementation with Resveratrol Improves Bone Mineral Density in Postmenopausal Women, the second in the series of publications from the two-year RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical trial of Veri-te resveratrol. The latest findings, supported by the National Health and Medical Research Council and the Australian Research Council (NHMRC-ARC) and a grant from Evolva, are published in the Journal of Bone and Mineral Research.
Conducted by researchers at the University of Newcastle’s Clinical Nutrition Research Centre, RESHAW was designed to investigate the impact of resveratrol supplementation on body composition, including bone mineral density in critical regions. In the crossover comparison, volunteers (in 125 postmenopausal women) were randomized to take two capsules containing 75mg of Evolva’s Veri-te resveratrol ingredient daily or a placebo supplement for 12 months, followed by the alternate treatment for a further 12 month-period.